Journal article
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including …
Authors
Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Frederich R; Wiviott SD; Hoffman EB
Journal
New England Journal of Medicine, Vol. 369, No. 14, pp. 1317–1326
Publisher
Massachusetts Medical Society
Publication Date
October 3, 2013
DOI
10.1056/nejmoa1307684
ISSN
0028-4793